Standard‐Dose Versus High‐Dose Cisplatin for Intermediate/Poor‐Risk Extracranial Malignant Germ Cell Tumors: Re‐Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification
Treatment with HDPEb did not improve outcomes for intermediate/poor-risk GCT patients compared to standard-dose PEb.
Authors
- Jingye Yang
- Michelle M. Nuño (ORCID: https://orcid.org/0000-0003-2031-929X)
- A. Lindsay Frazier (ORCID: https://orcid.org/0000-0003-4748-8552)
- Farzana Pashankar (ORCID: https://orcid.org/0000-0003-2883-0957)
- Furqan Shaikh (ORCID: https://orcid.org/0000-0001-7069-0359)
- Daniel Prior
Institutions
- University of Southern California (US)
- Hospital for Sick Children (CA)
- Yale University (US)
- Children's Oncology Group (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1002/pbc.31665
- Citations
- 2
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01